![topcat study topcat study](https://cdn.sanity.io/images/0vv8moc6/ajmc/ecf1ad37b05703b11d32edd57af578ffb034588b-640x360.jpg)
![topcat study topcat study](https://www.jacc.org/cms/asset/48bafe59-206d-4b01-ad3c-0b3132ad8df9/fx1.jpg)
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al.Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. doi: 10.1016/j.jacc.2013.11.053.Įdelmann F, Tomaschitz A, Wachter R, Gelbrich G, Knoke M, Dungen HD, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. Īmbrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al.Papers of particular interest, published recently, have been highlighted as: The overall design, execution, and study oversight of TOPCAT have provided key insights into the conduct of future HFpEF trials.
#TOPCAT STUDY TRIAL#
A planned registry-based trial should provide additional evidence regarding the role of spironolactone in HFpEF. Given potential benefits in the Americas subgroup in TOPCAT, mineralocorticoid receptor antagonists can be considered in appropriately selected patients with HFpEF to reduce risk of heart failure hospitalization. Significant regional variation may impact the success of global HFpEF trials. Subsequent analyses of TOPCAT have revealed marked regional heterogeneity in patient profiles, event rates, drug adherence, and treatment effects. We identify key lessons from the TOPCAT experience that can be applied to future HFpEF trials. Spironolactone did not demonstrate benefit with respect to the primary composite endpoint in the global TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial in patients with chronic heart failure with preserved ejection fraction (HFpEF).